-
公开(公告)号：US20180000788A1
公开(公告)日：2018-01-04
申请号：US15541725
申请日：2016-01-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter W. Glunz , Doree F. Sitkoff , Navnath Dnyanoba , Mandar Shrikrishna Bodas , Rajeev S. Bhide , Sharanabasappa Patil , Kumaresan Chinnakotti , Prasanna Savanor Maddu Rao
IPC: A61K31/4178 , C07D471/04 , C07D413/10 , C07D403/10 , C07D401/14 , C07D401/10 , A61K31/498 , C07D487/04 , A61K31/422
CPC classification number: A61K31/4178 , A61K31/422 , A61K31/498 , C07D401/10 , C07D401/14 , C07D403/10 , C07D413/10 , C07D471/04 , C07D487/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US10947297B2
公开(公告)日：2021-03-16
申请号：US15819925
申请日：2017-11-21
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
IPC: A61K39/00 , A61K39/44 , C07K4/00 , C07K14/00 , C07K14/78 , A61K38/39 , C12N9/64 , A61K47/60 , A61K47/54 , C07K16/18 , C07K16/40
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US10112929B2
公开(公告)日：2018-10-30
申请号：US15554741
申请日：2016-03-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter W. Glunz , Doree F. Sitkoff , Mandar Shrikrishna Bodas , Navnath Dnyanoba Yadav , Sharanabasappa Patil , Prasanna Savanor Maddu Rao
IPC: A61K31/506 , C07D403/14 , C07D403/10 , C07D417/14 , C07D405/14 , C07D471/04 , C07D401/14
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US09856309B2
公开(公告)日：2018-01-02
申请号：US14956698
申请日：2015-12-02
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC classification number: C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US09234027B2
公开(公告)日：2016-01-12
申请号：US13835639
申请日：2013-03-15
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC classification number: C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
Abstract translation: 本发明涉及结合PCSK9的基于纤连蛋白的支架结构域蛋白。 本发明还涉及创新的蛋白质在治疗应用中用于治疗动脉粥样硬化，高胆固醇血症和其它胆固醇相关疾病的用途。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码该创新蛋白质的多核苷酸的载体。
-
Patent Agency Ranking
公开(公告)号：US10123993B2
公开(公告)日：2018-11-13
申请号：US15541725
申请日：2016-01-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter W. Glunz , Doree F. Sitkoff , Navnath Dnyanoba Yadav , Mandar Shrikrishna Bodas , Rajeev S. Bhide , Sharanabasappa Patil , Kumaresan Chinnakotti , Prasanna Savanor Maddu Rao , Jeevan Prakash Shetty
IPC: A61K31/4178 , A61K31/422 , A61K31/498 , C07D401/14 , C07D401/10 , C07D403/10 , C07D413/10 , C07D471/04 , C07D487/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US10112939B2
公开(公告)日：2018-10-30
申请号：US15503419
申请日：2015-08-20
Applicant: Bristol-Myers Squibb Company
Inventor： Zilun Hu , Doree F. Sitkoff , Mimi L. Quan
IPC: C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D409/14 , C07D471/04 , C07D231/12 , C07D413/14
Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US20180201665A1
公开(公告)日：2018-07-19
申请号：US15819925
申请日：2017-11-21
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US20170226105A1
公开(公告)日：2017-08-10
申请号：US15503419
申请日：2015-08-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zilun Hu , Doree F. Sitkoff , Mimi L. Quan
IPC: C07D471/04 , C07D403/10 , C07D231/12 , C07D413/14 , C07D401/14 , C07D409/14 , C07D403/14 , C07D401/10 , C07D405/14
CPC classification number: C07D401/10 , C07D231/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04
Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US20160159883A1
公开(公告)日：2016-06-09
申请号：US14956698
申请日：2015-12-02
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC classification number: C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.028 seconds)
